Excessive use of digital devices and mental health issues can both contribute to the development of dry eye syndrome.

The FDA has again issued a CRL to Aldeyra regarding the New Drug Application for reproxalap for the treatment of dry eye disease.

Having both aqueous-deficient and evaporative dry eye, corneal pain, or a history of dry eye treatment can worsen quality of life.

Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ...